Published in Clin Vaccine Immunol on January 02, 2013
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res (2013) 1.22
Limiting damage during infection: lessons from infection tolerance for novel therapeutics. PLoS Biol (2014) 1.04
Systemic inflammation and cerebral palsy risk in extremely preterm infants. J Child Neurol (2014) 0.98
Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy. J Virol (2014) 0.92
New therapeutic approaches for treatment of tularaemia: a review. Front Cell Infect Microbiol (2014) 0.91
Haloarchaeal gas vesicle nanoparticles displaying Salmonella SopB antigen reduce bacterial burden when administered with live attenuated bacteria. Vaccine (2014) 0.90
Harnessing nanoparticles for immune modulation. Trends Immunol (2015) 0.88
An Immature Myeloid/Myeloid-Suppressor Cell Response Associated with Necrotizing Inflammation Mediates Lethal Pulmonary Tularemia. PLoS Pathog (2016) 0.85
Targeting the "Rising DAMP" during a Francisella tularensis Infection. Antimicrob Agents Chemother (2013) 0.83
Mitogen-activated protein kinases (MAPKs) are modulated during Francisella tularensis infection, but inhibition of extracellular-signal-regulated kinases (ERKs) is of limited therapeutic benefit. Eur J Clin Microbiol Infect Dis (2016) 0.80
A reverse-phase protein microarray-based screen identifies host signaling dynamics upon Burkholderia spp. infection. Front Microbiol (2015) 0.79
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. Clin Exp Immunol (2016) 0.77
Differential role for interleukin-6 during Francisella tularensis infection with virulent and vaccine strains. Infect Immun (2013) 0.77
Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature. J Clin Invest (2017) 0.76
Milk fat globule-epidermal growth factor-factor VIII downregulates interleukin-17 expression in sepsis by modulating STAT3 activation. Surgery (2015) 0.76
Anti-inflammatory effects of indirubin derivatives on influenza A virus-infected human pulmonary microvascular endothelial cells. Sci Rep (2016) 0.76
The Modified JiuWei QiangHuo Decoction Alleviated Severe Lung Injury Induced by H1N1 Influenza Virus by Regulating the NF- κ B Pathway in Mice. Evid Based Complement Alternat Med (2015) 0.76
A Dormant Microbial Component in the Development of Preeclampsia. Front Med (Lausanne) (2016) 0.76
Porcine epidemic diarrhea virus nucleoprotein contributes to HMGB1 transcription and release by interacting with C/EBP-β. Oncotarget (2016) 0.75
Influenza lung injury: mechanisms and therapeutic opportunities. Am J Physiol Lung Cell Mol Physiol (2015) 0.75
The Immune System, Cytokines, and Biomarkers in Autism Spectrum Disorder. Neurosci Bull (2017) 0.75
Tumour Necrosis Factor-Α, Interleukin-1 and Interleukin-6 Serum Levels and Its Correlation with Pain Severity in Chronic Tension-Type Headache Patients: Analysing Effect of Dexketoprofen Administration. Open Access Maced J Med Sci (2017) 0.75
Agents to reduce cytokine storm. F1000Res (2016) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 26.12
From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 15.90
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 15.27
Recognition of microorganisms and activation of the immune response. Nature (2007) 12.99
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 11.49
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 8.87
Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 8.74
Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med (2002) 7.99
Antibiotics for emerging pathogens. Science (2009) 7.39
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
IL-10: the master regulator of immunity to infection. J Immunol (2008) 6.11
Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol (2004) 5.38
JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest (2000) 5.12
H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4.79
Anti-inflammatory cytokines. Chest (2000) 4.74
Developmental regulation of Foxp3 expression during ontogeny. J Exp Med (2005) 4.32
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
Regulatory T cells and mechanisms of immune system control. Nat Med (2004) 4.23
Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell (2006) 3.83
Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med (2007) 3.63
The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev (2006) 3.59
Chemokine receptors: gateways to inflammation and infection. Nat Med (1996) 3.56
Interleukin-10 therapy--review of a new approach. Pharmacol Rev (2003) 3.51
Chemokine receptors and their role in inflammation and infectious diseases. Blood (2000) 3.40
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32
Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem (2007) 3.28
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol (2002) 2.88
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
Chemokines in pathology and medicine. J Intern Med (2001) 2.83
Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol (2007) 2.78
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Into the eye of the cytokine storm. Microbiol Mol Biol Rev (2012) 2.58
Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol (2007) 2.43
The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol (2006) 2.42
Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A (2008) 2.33
Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol (1999) 2.23
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) (2004) 2.19
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 1.98
A calculated response: control of inflammation by the innate immune system. J Clin Invest (2008) 1.93
Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol (2010) 1.92
IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr (2001) 1.87
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med (2004) 1.80
Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol (2001) 1.74
Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother (2010) 1.73
Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol (1998) 1.72
The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med (2002) 1.66
Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol (2006) 1.64
Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol (1995) 1.64
Metabolism and antiviral activity of ribavirin. Virus Res (2005) 1.57
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med (2003) 1.53
Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis (2008) 1.46
Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns. Infect Immun (2008) 1.41
Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis (2010) 1.41
T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol (2005) 1.38
Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun (2004) 1.34
The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie (2010) 1.30
The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res (2000) 1.28
Role of interleukin-8 in neutrophil signaling. Curr Opin Hematol (2000) 1.27
The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis (2001) 1.27
Extensively drug-resistant tuberculosis: a new face to an old pathogen. Annu Rev Med (2009) 1.24
Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor. Infect Immun (1994) 1.22
Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma. Mediators Inflamm (2001) 1.17
Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis. Mol Immunol (2008) 1.16
GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochem Pharmacol (2009) 1.14
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood (2007) 1.11
Features of sepsis caused by pulmonary infection with Francisella tularensis Type A strain. Microb Pathog (2011) 1.11
Role of endothelial chemokines and their receptors during inflammation. J Invest Surg (2011) 1.11
Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock (2006) 1.09
Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol (2000) 1.09
A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun (2006) 1.08
Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A (2009) 1.08
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Effects of the α7 nicotinic acetylcholine receptor agonist GTS-21 on the innate immune response in humans. Shock (2011) 1.00
CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J Immune Based Ther Vaccines (2010) 1.00
Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost (2006) 1.00
CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J Immunol (2010) 0.99
[Cytokine storm in avian influenza]. Mikrobiyol Bul (2008) 0.98
Inhibition of in vivo tumor growth by the beta chemokine, TCA3. J Immunol (1994) 0.97
Chemokines as novel therapeutic targets in inflammatory diseases. Biochem Pharmacol (2002) 0.96
Three fatal cases of pandemic 2009 influenza A virus infection in Shenzhen are associated with cytokine storm. Respir Physiol Neurobiol (2010) 0.94
Roles of prostaglandins and leukotrienes in acute inflammation caused by bacterial infection. Curr Opin Infect Dis (2001) 0.94
The development of anti-inflammatory drugs for infectious diseases. Discov Med (2010) 0.88
The protective effect of the cholinergic anti-inflammatory pathway against septic shock in rats. Shock (2008) 0.88
The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo. Immunology (2001) 0.87
Totally drug-resistant tuberculosis in India: who let the djinn out? Respirology (2012) 0.87
Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One (2010) 0.86
Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax (2011) 0.86
Blocking prostaglandin E2 after trauma attenuates pro-inflammatory cytokines and improves survival. Shock (2000) 0.83
Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis (1996) 0.83
Immunoneutralization of chemokines for the prevention and treatment of central nervous system autoimmune disease. Methods (2003) 0.83
First evidence of a pro-inflammatory response to severe infection with influenza virus H1N1. Crit Care (2010) 0.82
Transmission of Yersinia pestis from an infectious biofilm in the flea vector. J Infect Dis (2004) 2.52
Suicide after leaving the UK armed forces--a cohort study. PLoS Med (2009) 1.97
Role of quorum sensing in the pathogenicity of Burkholderia pseudomallei. J Med Microbiol (2004) 1.47
RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res (2003) 1.46
Patterns of Dwarf expression and brassinosteroid accumulation in tomato reveal the importance of brassinosteroid synthesis during fruit development. Plant J (2005) 1.17
Tomato BRASSINOSTEROID INSENSITIVE1 is required for systemin-induced root elongation in Solanum pimpinellifolium but is not essential for wound signaling. Plant Cell (2007) 1.16
Recombinant Bacillus subtilis expressing the Clostridium perfringens alpha toxoid is a candidate orally delivered vaccine against necrotic enteritis. Infect Immun (2008) 1.05
CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res (2005) 1.02
Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun (2006) 1.02
Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei. Infect Immun (2006) 0.99
Evaluation of two multiplex real-time PCR screening capabilities for the detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis in blood samples generated from murine infection models. J Med Microbiol (2012) 0.94
Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis (2011) 0.94
Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei. BMC Immunol (2008) 0.91
The potential of TaqMan Array Cards for detection of multiple biological agents by real-time PCR. PLoS One (2012) 0.89
Functional characterization of OXA-57, a class D beta-lactamase from Burkholderia pseudomallei. Antimicrob Agents Chemother (2005) 0.88
Neutrophils are the predominant cell-type to associate with Burkholderia pseudomallei in a BALB/c mouse model of respiratory melioidosis. Microb Pathog (2011) 0.88
Molecular cloning of the cell surface antigen identified by the osteoprogenitor-specific monoclonal antibody, HOP-26. J Cell Biochem (2003) 0.86
What are the effects of having an illness or injury whilst deployed on post deployment mental health? A population based record linkage study of UK army personnel who have served in Iraq or Afghanistan. BMC Psychiatry (2012) 0.84
Regions of the Cf-9B disease resistance protein able to cause spontaneous necrosis in Nicotiana benthamiana lie within the region controlling pathogen recognition in tomato. Mol Plant Microbe Interact (2009) 0.84
The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes. J Clin Endocrinol Metab (2008) 0.84
VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine (2005) 0.83
Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C. Microb Pathog (2007) 0.83
Developing and understanding biofluid vibrational spectroscopy: a critical review. Chem Soc Rev (2015) 0.83
The use of colorimetric sensor arrays to discriminate between pathogenic bacteria. PLoS One (2013) 0.82
Effects of Clostridium perfringens phospholipase C in mammalian cells. Anaerobe (2004) 0.81
Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrob Agents Chemother (2012) 0.81
Gene expression following low dose inhalational Francisella tularensis (SchuS4) exposure in Balb/c mice and the potential role of the epithelium and cell adhesion. Microbes Infect (2011) 0.80
Helping to improve the group stereotype: on the strategic dimension of prosocial behavior. Pers Soc Psychol Bull (2007) 0.80
Reactive oxygen species and the MEK/ERK pathway are involved in the toxicity of clostridium perfringens α-toxin, a prototype bacterial phospholipase C. J Infect Dis (2012) 0.80
Tomato BRI1 and systemin wound signalling. Plant Signal Behav (2008) 0.79
Orally delivered water soluble Coenzyme Q10 (Ubisol-Q10) blocks on-going neurodegeneration in rats exposed to paraquat: potential for therapeutic application in Parkinson's disease. BMC Neurosci (2014) 0.79
Yersinia pseudotuberculosis is resistant to killing by human neutrophils. Microbes Infect (2011) 0.78
Self-harm in UK armed forces personnel: descriptive and case-control study of general hospital presentations. Br J Psychiatry (2009) 0.78
The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays. Microb Pathog (2013) 0.77
Protective cellular responses to Burkholderia mallei infection. Microbes Infect (2010) 0.76
Stride Frequency And Injury Rates In Recreational Runners Training For A Half-marathon: 2183 Board #335 June 2, 2: 00 PM - 3: 30 PM. Med Sci Sports Exerc (2016) 0.75
CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner. Int J Antimicrob Agents (2013) 0.75